Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Tract Pharmaceuticals, Inc. currently has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This 1 pending office action is assigned to 1 distinct examiner. The 1 distinct art unit involved indicates the specific technical category for this application. With only 1 pending office action, the company's current prosecution activity is focused on a single matter. This concentration means that the outcome of this 1 case represents the company's current progress in the biotechnology sector.
JARRELL, NOBLE E is the busiest examiner for this portfolio, holding 1 pending office action. Because there is 1 distinct examiner, the company's immediate prosecution success depends on the review of this specific individual. The 1 distinct art unit involved suggests a singular path for this pharmaceutical innovation. Practitioners should focus on the specific requirements of JARRELL, NOBLE E to advance the 1 pending office action. The involvement of only 1 distinct examiner and 1 distinct art unit for the 1 pending office action means that there are no other active matters to provide a baseline for comparison within the portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JARRELL, NOBLE E | 1 | 80.9% | +10.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19308852 | COMBINATION OF IAP INHIBITORS AND CELLULAR KINASE INHIBITORS, SUCH AS PONATINIB, FOR USE IN THE TREATMENT OF CANCER OR PULMONARY DISEASES, SUCH AS COPD, CYSTIC FIBROSIS, PULMONARY FIBROSIS AND COVID-19 | JARRELL, NOBLE E | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19308852 | COMBINATION OF IAP INHIBITORS AND CELLULAR KINASE INHIBITORS, SUCH AS PONATINIB, FOR USE IN THE TREATMENT OF CANCER OR PULMONARY DISEASES, SUCH AS COPD, CYSTIC FIBROSIS, PULMONARY FIBROSIS AND COVID-19 | JARRELL, NOBLE E | — |
| Art Unit | Apps |
|---|---|
| 1699 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19308852 | COMBINATION OF IAP INHIBITORS AND CELLULAR KINASE INHIBITORS, SUCH AS PONATINIB, FOR USE IN THE TREATMENT OF CANCER OR PULMONARY DISEASES, SUCH AS COPD, CYSTIC FIBROSIS, PULMONARY FIBROSIS AND COVID-19 | JARRELL, NOBLE E | 1699 | §103§112 | Final Rejection | — | Pending | Aug 25, 2025 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialTract Pharmaceuticals, Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Noble E Jarrell has the most, with 1 of Tract Pharmaceuticals, Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
